Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

ELISA kit information. by Shuailin Li (11907158)

“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”

Included studies basic characteristics. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

DataSheet1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

DataSheet2_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”

All data extracted. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Table1_Effects of Qingjin Huatan decoction on pulmonary function and inflammatory mediators in acute exacerbations of chronic obstructive pulmonary disease: a systematic review and... by Xuqin Du (8803772)

“…Compared to conventional treatment, QHD significantly improved pulmonary function, with increases in FEV1 (MD = 0.30, 95% CI: 0.26 to 0.34, p = 0.000), FVC (MD = 0.34, 95% CI: 0.27 to 0.41, p = 0.000), FEV1/FVC (MD = 6.07, 95% CI: 5.55 to 6.58, p = 0.000), and PaO₂ (MD = 7.20, 95% CI: 4.94 to 9.47, p = 0.000), and a decrease in PaCO₂ (MD = −5.37, 95% CI: 7.99 to −2.74, p = 0.000). …”